https://www.healio.com/news/ophthalmology/20220203/lower-bevacizumab-doses-agents-with-less-systemic-exposure-may-be-safer-options-for-rop
Feb 3rd, 2022 - WAIKOLOA, Hawaii — Systemic effects of anti-VEGF in retinopathy of prematurity have not been ruled out, so it may be wise to use bevacizumab in lower doses or switch to agents with less systemic exposure, according to one presenter. “The BEAT-ROP study demonstrated a beneficial effect for bevacizumab vs. laser in the treatment of zone I, stage 3+ ROP. But one thing I didn’t like was the complet...
https://clinicaltrials.gov/ct2/show/NCT03412565
Aug 12th, 2022 - The hypothesis is that the addition of daratumumab administered SC to standard MM regimens will improve responses compared to response data observed in completed phase 3 studies without daratumumab. Disease evaluations will include measurements of myeloma proteins, bone marrow examinations, skeletal surveys, assessment of extramedullary plasmacytomas, and measurements of serum calcium corrected...
https://doi.org/10.1093/cid/ciac641
Clinical Infectious Diseases : an Official Publication Of... Le Goff M, Kendjo E et. al.
Aug 14th, 2022 - The impact of chemoprophylaxis targeting Plasmodium falciparum on Plasmodium vivax and Plasmodium ovale, which may remain quiescent as hypnozoites in the liver, is debated. We conducted a nested case-control analysis of the outcomes of P. vivax and P. ovale infections in imported malaria cases in France among civilian travellers from January 1st, 2006, to December 31st, 2017. Using adjusted log...
https://doi.org/10.1007/s11739-022-03036-3
Internal and Emergency Medicine; Suzaki A, Komine-Aizawa S et. al.
Aug 14th, 2022 - Clostridium perfringens bacteremia is rare but often fatal. In particular, once bacteremia with massive intravascular hemolysis (MIH) occurs, the mortality rate is extremely high. However, because of its rarity, the detailed pathophysiology of this fulminant form of bacteremia is unclear. To elucidate the detailed pathogenesis of MIH, we retrospectively reviewed the data of all patients with C....
https://doi.org/10.1136/bcr-2022-250009
BMJ Case Reports; Cerniglia M, Klepadlo M et. al.
Aug 13th, 2022 - For hepatocellular carcinoma, the IMbrave150 trial demonstrated that combination atezolizumab and bevacizumab had significantly better overall survival compared with sorafenib in patients with unresectable disease. However, as more immune checkpoint inhibitors are approved as first-line agents in gastrointestinal cancers, there have been few reports on whether sequential PD-1/PD-L1 blockade is ...
https://doi.org/10.1016/bs.acr.2022.02.001
Advances in Cancer Research; Cadamuro M, Strazzabosco M
Aug 13th, 2022 - Cholangiocarcinoma (CCA), a neoplasm burdened by a poor prognosis and currently lacking adequate therapeutic treatments, can originate at different levels of the biliary tree, in the intrahepatic, hilar, or extrahepatic area. The main risk factors for the development of CCA are the presence of chronic cholangiopathies of various etiology. To date, the most studied prodromal diseases of CCA are ...
https://doi.org/10.1016/bs.acr.2022.01.012
Advances in Cancer Research; Høgdall D, O'Rourke CJ et. al.
Aug 13th, 2022 - A diagnosis of cholangiocarcinoma (CCA) is implicit with poor prognosis and limited treatment options, underscoring the near equivalence of incidence and mortality rates in this disease. In less than 9years from genomic identification to FDA-approval of the corresponding inhibitors, fibroblast growth factor receptor 2 (FGFR2) rearrangements and isocitrate dehydrogenase 1 (IDH1) mutations became...
https://doi.org/10.1177/09612033221119123
Lupus Liu D, Zhou Q et. al.
Aug 13th, 2022 - Systemic lupus erythematosus is a chronic inflammatory autoimmune disease that has various manifestations. Lupus nephritis is a common and severe presentation, which results in increased morbidity and mortality. Belimumab added on standard therapy has been proved to induce disease remission and improve renal parameters. However, the use of belimumab has not been explored in patients requiring d...
https://doi.org/10.1007/s00432-022-04246-0
Journal of Cancer Research and Clinical Oncology; Samaran Q, Samaran R et. al.
Aug 13th, 2022 - Anti-PD1 agents are currently recommended as first-line treatment in advanced cutaneous squamous cell carcinoma (acSCC) by updated European guidelines. Although acSCC frequently affects elderly patients with multiple comorbidities, this subset of patients is often excluded of registration clinical trials. To assess anti-PD-1 efficacy and safety in elderly acSCC patients in real-life conditions ...
https://doi.org/10.1093/cid/ciac655
Clinical Infectious Diseases : an Official Publication Of... Fjelltveit EB, Blomberg B et. al.
Aug 13th, 2022 - The burden and duration of persistent symptoms after non-severe COVID-19 remains uncertain. This study aimed to assess post-infection symptom trajectories in home-isolated COVID-19 cases compared to age- and time-period matched seronegative controls, and investigate immunological correlates of long COVID. A prospective case-control study conducted between February 28th and April 4th 2020 includ...
https://doi.org/10.3350/cmh.2022.0032
Clinical and Molecular Hepatology; Park SJ, Hahn YS
Aug 13th, 2022 - Hepatitis C virus (HCV) infection is remarkably efficient in establishing viral persistence, leading to the development of liver cirrhosis and hepatocellular carcinoma (HCC). Direct-acting antiviral agents (DAA) are promising HCV therapies to clear the virus. However, recent reports indicate potential increased risk of HCC development among HCV patients with cirrhosis following DAA therapy. CD8...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357708
Canadian Journal of Gastroenterology & Hepatology; Rosseto-Welter EA, D'argenio-Garcia L et. al.
Aug 13th, 2022 - Crohn's disease (CD) is a chronic inflammatory disease with a complex interface of broad factors. There are two main treatments for Chron's disease: biological therapy and nonbiological therapy. Biological agent therapy (e.g., anti-TNF) is the most frequently prescribed treatment; however, it is not universally accessible. In fact, in Brazil, many patients are only given the option of receiving...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357817
Journal of Immunology Research; Wang Y, Wang Y et. al.
Aug 13th, 2022 - BK virus-associated nephropathy (BKVN) remains a major infectious complication due to powerful immunosuppression in kidney transplant recipients, and its histologic appearance can mimic rejection, leading to diagnostic and treatment dilemmas thus molecular diagnostic methods would be beneficial. We collected gene expression profiles of 169 kidney biopsies taken from BKVN, rejection, and stable ...
https://clinicaltrials.gov/ct2/show/NCT01896999
Aug 12th, 2022 - PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the combinations of brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase I) II. To evaluate the complete response (CR) rate for the regimens of brentuximab vedotin and nivolumab compared to brentuximab vedotin, ip...
https://clinicaltrials.gov/ct2/show/NCT01886872
Aug 12th, 2022 - PRIMARY OBJECTIVE: I. To determine whether progression free survival (PFS) is superior after therapy with bendamustine hydrochloride (bendamustine) in combination with rituximab, ibrutinib alone, or ibrutinib in combination with rituximab in patients age 65 or older with previously untreated chronic lymphocytic leukemia (CLL). SECONDARY OBJECTIVES: I. To determine 2-year PFS in each of the thre...
https://clinicaltrials.gov/ct2/show/NCT01974440
Aug 12th, 2022 - This is a randomized (individuals assigned to study treatment by chance), double-blind (individuals and study personnel will not know the identity of study treatments), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial)-controlled study in approximately 400 adult participants with follicular lymphoma or marginal zone lymph...
https://clinicaltrials.gov/ct2/show/NCT01829568
Aug 12th, 2022 - PRIMARY OBJECTIVE: I. To determine the recommended phase II doses of ibrutinib and lenalidomide for combination with rituximab in previously untreated follicular lymphoma. SECONDARY OBJECTIVES: I. To determine pharmacokinetics of ibrutinib and its major metabolite (PCI-45227) when combined with lenalidomide and rituximab. II. To determine the pharmacodynamics of basophil activation and Bruton t...
https://clinicaltrials.gov/ct2/show/NCT03456102
Aug 12th, 2022 - There is an urgent need for novel therapies to shorten TB treatment and improve long-term lung function outcomes. Host-directed therapies (HDT) have received significant attention recently given the ability of M. tuberculosis to subvert host immune responses and cause destructive lung pathology. Statins are among the most promising HDT agents for TB. In addition to having a highly favorable saf...
https://clinicaltrials.gov/ct2/show/NCT01979536
Aug 12th, 2022 - PRIMARY OBJECTIVES: I. To determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy (anaplastic large cell lymphoma [ALCL]99) and to determine the tolerability of crizotinib given in combination with chemotherapy (ALCL99). II. To estimate the event free survival (EFS) of Arm brentuximab vedotin (BV) and Arm crizotinib (CZ) and contrast these to historical...
https://clinicaltrials.gov/ct2/show/NCT04639843
Aug 12th, 2022 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)-like regimen, with less than 30% having durable complete responses (CRs). Of the chemotherapy agents used, doxorubi...
